Trials / Completed
CompletedNCT00631319
A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
A Phase III, Flexible Dose Titration Followed by a Randomized Double-Blind Study of Controlled Release OROS Hydromorphone HCL Compared to Placebo in Patients With OA Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 343 (actual)
- Sponsor
- Mallinckrodt · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OROS hydromorphone | hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-04-01
- Completion
- 2009-06-01
- First posted
- 2008-03-07
- Last updated
- 2020-09-16
- Results posted
- 2020-08-26
Source: ClinicalTrials.gov record NCT00631319. Inclusion in this directory is not an endorsement.